10-Q: Evoke Pharma to be Acquired by QOL Medical for $11.00/Share

Evoke Pharma reported strong Q3 2025 sales growth for Gimoti and announced a definitive merger agreement to be acquired by QOL Medical for $11.00 per share in cash.

Summary

• Evoke Pharma entered into a definitive merger agreement with QOL Medical, LLC, where QOL Medical will acquire all outstanding shares for $11.00 per share in cash.
• The transaction is expected to close in the fourth quarter of 2025, subject to customary conditions.
• Net product sales for Gimoti increased by 61% to $4.3 million for the three months ended September 30, 2025, compared to $2.7 million in the same period of 2024.
• Net product sales for the nine months ended September 30, 2025, rose 60% to $11.1 million, up from $6.9 million in the prior year.
• The net loss for the three months ended September 30, 2025, improved to $1.2 million from $1.3 million in the prior year.
• The net loss for the nine months ended September 30, 2025, improved to $4.0 million from $4.2 million in the prior year.
• Cash and cash equivalents stood at $11.6 million as of September 30, 2025.
• Management believes there is substantial doubt about the company's ability to continue as a going concern for one year after the financial statements' issuance date, primarily due to potential early repayment of the Eversana Credit Facility if the commercial agreement is terminated.
• New inbound prescriptions for Gimoti increased by 13.6% in Q3 2025 compared to Q2 2025, and new prescribers increased by 8.1%.
• The company regained compliance with Nasdaq's minimum stockholders' equity requirement and is no longer under a panel monitor as of June 20, 2025.

Sentiment

Score: 7

Explanation: The definitive merger agreement with QOL Medical at $11.00 per share provides a strong positive catalyst and a clear liquidity event for shareholders, effectively addressing the company's persistent going concern issues and historical operating losses. While operational metrics for Gimoti showed significant sales growth and improved net loss, the underlying financial instability and reliance on external funding were critical concerns that the acquisition largely mitigates.

Positives

• Significant increase in net product sales for Gimoti: 61% for Q3 2025 ($4.3 million) and 60% for 9M 2025 ($11.1 million) compared to the prior year periods.
• Improved net loss for both the three-month ($1.2 million vs $1.3 million) and nine-month ($4.0 million vs $4.2 million) periods ended September 30, 2025, compared to 2024.
• Increased prescription metrics for Gimoti, including a 13.6% rise in new inbound prescriptions and an 8.1% increase in new prescribers in Q3 2025 over Q2 2025.
• Positive real-world evidence data for Gimoti showing reduced healthcare resource utilization (60% fewer physician/ER visits, 68% fewer inpatient admissions) and $15,000 in cost savings compared to oral metoclopramide.
• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement and removed from panel monitor as of June 20, 2025.
• The definitive merger agreement with QOL Medical provides a clear exit strategy and liquidity for shareholders at $11.00 per share.

Negatives

• Substantial doubt about the company's ability to continue as a going concern for one year after the financial statements' issuance date.
• The company has incurred recurring losses and negative cash flows from operations since inception and expects to continue to incur net losses.
• Cash and cash equivalents decreased to $11.6 million as of September 30, 2025, from $13.6 million at December 31, 2024.
• Total stockholders' equity decreased to $3.4 million as of September 30, 2025, from $7.0 million at December 31, 2024.
• If the Eversana Agreement is terminated, the company would owe Eversana $7.5 million for the loan and $1.0 million in deferred costs, due within 90 days, which would significantly impact liquidity.
• Selling, general and administrative expenses increased by $1.5 million (39%) for Q3 2025 and $4.0 million (38%) for 9M 2025, primarily due to marketing and Eversana profit sharing.
• The company's business is entirely dependent on the success of Gimoti.

Risks

• The merger with QOL Medical may not be completed within the anticipated timeframe or at all, which could adversely affect the business, financial results, and operations.
• If the merger is not completed, the company may be required to pay QOL Medical a termination fee of $1.5 million.
• The pendency of the merger could cause substantial disruptions, create uncertainty, and affect the ability to retain employees and maintain relationships with partners.
• Restrictions on business activities while the merger agreement is in effect could prevent the company from pursuing strategic opportunities or responding to competitive pressures.
• The company has incurred and will continue to incur significant direct and indirect costs related to the pending transaction, regardless of completion.
• Litigation may arise in connection with the tender offer or merger, which could be costly, divert management's attention, and harm the business.
• Substantial doubt exists about the company's ability to continue as a going concern for one year after the financial statements' issuance date.
• The company anticipates needing to raise additional funds through debt, equity, or collaboration arrangements if the merger is not completed.
• There is no assurance that additional financing will be available when needed or on acceptable terms.
• If unable to secure adequate additional funding, the company may be forced to reduce spending, extend payment terms, or suspend/curtail commercialization activities, potentially leading to liquidation.
• Eversana or the company may exercise the Net Profit Quarterly Termination Right (NPQTR) due to negative net profits for two consecutive quarters, which would accelerate the repayment of the $7.5 million loan and $1.0 million in deferred costs to Eversana.
• The company would need to establish a substantial commercial infrastructure if the Eversana Agreement is terminated, incurring significant and unclear costs.
• The costs and timelines for the post-marketing commitment single-dose PK clinical trial for Gimoti's lower dose strength are uncertain but may be significant.
• The commercial success of Gimoti is subject to competition from well-established products, including oral and intravenous forms of metoclopramide.
• Ability to manufacture sufficient quantities of Gimoti and reliance on contract manufacturers and suppliers.
• Ability to obtain, maintain, and enforce patents and other intellectual property rights.

Future Outlook

The company expects to be acquired by QOL Medical, LLC for $11.00 per share in cash, with the transaction anticipated to close in the fourth quarter of 2025. If the merger is not completed, the company will need to raise additional funds to continue operations, as existing cash is only sufficient into Q4 2026, excluding potential early repayment of the Eversana Credit Facility. The company is also awaiting FDA feedback for a post-marketing clinical trial for a lower dose strength of Gimoti, which could incur significant R&D costs.

Management Comments

• "Management believes that there is substantial doubt about the Company's ability to continue as a going concern for one year after the date these financial statements are issued."
• "We believe, based on our current operating plan, excluding any potential early repayment of the Eversana Credit Facility, that our existing cash and cash equivalents as of September 30, 2025, as well as cash flows from future net sales of Gimoti, will be sufficient to fund our operations into the fourth quarter of 2026."
• "If the Merger is not completed, we anticipate that we will be required to raise additional funds in order to continue as a going concern."
• "Because our business is entirely dependent on the success of Gimoti, if we are unable to secure additional financing or identify and execute on other development or strategic alternatives for Gimoti or our company, we will be required to curtail all of our activities and may be required to liquidate, dissolve or otherwise wind down our operations."

Industry Context

The company operates in the specialty pharmaceutical sector, focusing on gastroenterological disorders. Gimoti, as the first and only nasally-administered metoclopramide for diabetic gastroparesis, addresses a specific unmet need. The positive real-world data demonstrating reduced healthcare utilization and cost savings compared to oral metoclopramide positions Gimoti favorably, especially with increasing interest in GLP-1 treatments which can cause delayed gastric emptying. The acquisition by QOL Medical suggests consolidation within the specialty pharma space, potentially driven by the value of niche products with demonstrated clinical benefits.

Comparison to Industry Standards

• Gimoti is the first and only nasally-administered product for acute and recurrent diabetic gastroparesis, differentiating it from existing oral and intravenous metoclopramide options.
• Real-world evidence showed Gimoti patients had significantly fewer physician office visits, emergency department visits (60% reduction), and inpatient hospitalizations (68% reduction) compared to patients taking oral metoclopramide.
• A study presented at the American College of Gastroenterology conference indicated a $15,000 savings for patients taking Gimoti compared to oral metoclopramide over a six-month period.
• Data presented at Digestive Disease Week indicated a far lower incidence of tardive dyskinesia (0.12%) for gastroparesis patients taking any form of metoclopramide than previously published, suggesting a potentially better safety profile or at least a lower observed incidence in a large database.
• Gimoti showed similar benefits for patients also taking GLP-1 treatments, addressing a growing area of interest for gastroenterologists.

Management Changes

Corporate Governance

Related Party Transactions

• Commercial services and loan agreement with Eversana Life Science Services, LLC, where Eversana is the commercial partner and provided a $5.0 million revolving credit facility.
• Letter agreement with Eversana on October 29, 2025, regarding payment of $1.0 million in deferred costs and outstanding loan principal/interest upon Change of Control or agreement expiration.
• Letter agreement with Nantahala Capital Management, LLC on September 27, 2024, granting board and committee appointment rights based on ownership percentage.

Stakeholder Impact

• Shareholders will receive $11.00 cash per share upon completion of the merger, providing a premium and liquidity. Those holding warrants with exercise prices below $11.00 will also receive cash.
• Employees: Amended and Restated Employment Agreements for key executives (Matthew J. D'Onofrio, Mark Kowieski, Marilyn R. Carlson) provide clarity on bonuses and parachute payments in connection with the merger. Transition Services Agreements also indicate a structured transition.
• Customers (Patients): Continued availability of Gimoti is implied under QOL Medical's ownership, but the long-term commercial strategy and support may evolve.
• Eversana (Commercial Partner/Creditor): Will receive repayment of the $5.0 million loan plus accrued interest ($7.5 million as of Sept 30, 2025) and an additional $1.0 million in deferred costs upon merger completion or termination of their agreement.
• Creditors: The merger provides a clear path for the repayment of the Eversana loan and other liabilities.

Next Steps

• Completion of the tender offer and merger with QOL Medical, LLC, expected in the fourth quarter of 2025.
• Conducting the post-marketing commitment single-dose pharmacokinetics (PK) clinical trial of Gimoti to characterize dose proportionality of a lower dose strength, pending FDA feedback.
• If the merger is not completed, the company will need to raise additional funds to continue as a going concern.
• Continued commercial activities for Gimoti, including manufacturing and marketing.
• Maintaining, expanding, and protecting the intellectual property portfolio.

Key Dates

Recommendation

The definitive merger agreement to be acquired by QOL Medical for $11.00 per share in cash represents a significant premium over the company's recent trading prices and provides a clear, immediate return for shareholders. This acquisition effectively resolves the company's persistent going concern issues and the need for future capital raises, which were major overhangs. While the company showed strong operational improvements with Gimoti sales growth and reduced net losses, the merger offers a de-risked exit strategy at a favorable valuation, making it a strong buy for investors seeking to capture the acquisition premium.

Keywords

Evoke Pharma, QOL Medical, Merger, Acquisition, Gimoti, Diabetic Gastroparesis, Metoclopramide, Nasal Spray, Pharmaceutical, Biotech, SEC Filing, 10-Q, Financial Results, Commercialization, Eversana, Going Concern, Nasdaq Listing, Warrants, Stock Options, Clinical Trial, Tardive Dyskinesia, GLP-1, Healthcare Costs